Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms

NCT01520220 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01520220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01520220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
June 11, 2012
Completion date
February 24, 2017
Enrollment
100 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia, myelofibrosis, myeloproliferative neoplasms of, polycythemia vera